Entries of Christopoulos, Petros on the publication server

Christopoulos, Petros , Kluck, Klaus, Kirchner, Martina, Lüders, Heike, Roeper, Julia, Falkenstern-Ge, Roger-Fei, Szewczyk, Marlen, Sticht, Florian, Saalfeld, Felix C. , Wesseler, Claas , Hackanson, Björn, Dintner, Sebastian, Faehling, Martin, Kuon, Jonas, Janning, Melanie, Kauffmann-Guerrero, Diego, Kazdal, Daniel, Kurz, Sylke, Eichhorn, Florian, Bozorgmehr, Farastuk, Shah, Rajiv , Tufman, Amanda, Wermke, Martin, Loges, Sonja, Brueckl, Wolfgang M., Schulz, Christian, Misch, Daniel, Frost, Nikolaj , Kollmeier, Jens , Reck, Martin, Griesinger, Frank, Grohé, Christian, Hong, Jin-Liern, Lin, Huamao M., Budczies, Jan , Stenzinger, Albrecht and Thomas, Michael (2022) The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions. European Journal of Cancer 170, pp. 106-118. Fulltext not available.

Roeper, Julia, Frost, Nikolaj, Wermke, Martin, Saalfeld, Felix C., Heudobler, Daniel, Pukrop, Tobias, Janning, Melanie, Kuon, Jonas, Fischer, Rieke, Nogova, Lucia, Christopoulos, Petros and Griesinger, Frank (2022) Thorakale Onkologie – metastasierte Stadien. Der Onkologe 28 (S1), pp. 55-60. Fulltext not available.

Frost, Nikolaj, Christopoulos, Petros, Kauffmann-Guerrero, Diego, Stratmann, Jan, Riedel, Richard, Schaefer, Monica, Alt, Jürgen, Gütz, Sylvia, Christoph, Daniel C., Laack, Eckart, Faehling, Martin, Fischer, Richard, Fenchel, Klaus, Haen, Sebastian, Heukamp, Lukas, Schulz, Christian and Griesinger, Frank (2021) Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program. Therapeutic Advances in Medical Oncology 13, p. 175883592098055. Fulltext not available.

Faehling, Martin, Schumann, Christian, Christopoulos, Petros, Hoffknecht, Petra, Alt, Jürgen, Horn, Marlitt, Eisenmann, Stephan , Schlenska-Lange, Anke, Schütt, Philipp, Steger, Felix, Brückl, Wolfgang M. and Christoph, Daniel C. (2020) Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP). Lung Cancer 150, pp. 114-122. Fulltext not available.